These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21045681)

  • 21. New evidence for nicotinic acid treatment to reduce atherosclerosis.
    Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent developments in modulating atherogenic lipoproteins.
    White CR; Goldberg DI; Anantharamaiah GM
    Curr Opin Lipidol; 2015 Oct; 26(5):369-75. PubMed ID: 26270809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells.
    Su G; Sun G; Liu H; Shu L; Zhang J; Guo L; Huang C; Xu J
    Med Sci Monit; 2015 Dec; 21():4081-9. PubMed ID: 26712802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
    Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
    Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niacin therapy in atherosclerosis.
    Meyers CD; Kamanna VS; Kashyap ML
    Curr Opin Lipidol; 2004 Dec; 15(6):659-65. PubMed ID: 15529025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotinic acid: current status in lipid management and cardiovascular disease prevention.
    Whayne TF
    Angiology; 2014 Aug; 65(7):557-9. PubMed ID: 24101713
    [No Abstract]   [Full Text] [Related]  

  • 28. Nicotinic acid: pharmacological effects and mechanisms of action.
    Gille A; Bodor ET; Ahmed K; Offermanns S
    Annu Rev Pharmacol Toxicol; 2008; 48():79-106. PubMed ID: 17705685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The basis principles of primary prevention of atherosclerosis].
    Titov VN
    Klin Med (Mosk); 2014; 92(12):19-29. PubMed ID: 25980295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A.
    Giri B; Belanger K; Seamon M; Bradley E; Purohit S; Chong R; Morgan JC; Baban B; Wakade C
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.
    Florentin M; Liberopoulos EN; Kei A; Mikhailidis DP; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):385-400. PubMed ID: 21314635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
    Zhou R; Stouffer GA; Smith SC
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Niacin and progression of CKD.
    Streja E; Kovesdy CP; Streja DA; Moradi H; Kalantar-Zadeh K; Kashyap ML
    Am J Kidney Dis; 2015 May; 65(5):785-98. PubMed ID: 25708553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release niacin raises adiponectin and leptin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Atherosclerosis; 2007 Aug; 193(2):361-5. PubMed ID: 16887123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
    Ganji SH; Kashyap ML; Kamanna VS
    Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is HPS2-THRIVE the death knell for niacin?
    Toth PP; Murthy AM; Sidhu MS; Boden WE
    J Clin Lipidol; 2015; 9(3):343-50. PubMed ID: 26073392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.